National Psoriasis Foundation appoints new experts to its Scientific Advisory Committee
Industry experience brings new perspectives to help guide NPF research activities
PORTLAND, Ore. (April 10, 2014)—For the first time, the National Psoriasis Foundation (NPF) has appointed industry scientists—Prisca Honoré, PharmD, Ph.D. of AbbVie; David M. Lee, M.D., Ph.D, of Novartis; Lotus Mallbris, M.D., Ph.D. of Pfizer; and Chris Russell, Ph.D., of Amgen—to its Scientific Advisory Committee to help guide its research activities. The selection of industry scientists advances the Psoriasis Foundation's ongoing efforts to include a variety of perspectives and areas of expertise on the Committee.
"This is an exciting opportunity to bring people into our advising family who have experience taking research discoveries and turning them into therapies that improve the health of people with psoriatic diseases," said Andrew Robertson, Ph.D., the chief scientific and medical officer for the National Psoriasis Foundation.
The Psoriasis Foundation Scientific Advisory Committee advises the Foundation on emerging research, advocates for federal support of psoriatic disease research, finds ways to distribute information about NPF-sponsored research, and advises the organization on research areas to fund through its grant program.
Prisca Honoré, PharmD, Ph.D., is the head of the dermatology group within Immunology Discovery at AbbVie, a global biopharmaceutical company formed in 2013 following a separation from Abbott Laboratories, in North Chicago. In her role, she is responsible for building AbbVie's dermatology portfolio of psoriasis treatments, defining strategies for new treatment identification, and leading a team of 16 multi-disciplinary scientists with expertise in inflammatory diseases, immunology, skin biology and pharmacology. Honoré brings more than a decade in pharmaceutical research and development in pain and immunology. She earned her doctorate of philosophy in pharmacology from University Paris V in France and her doctorate from its School of Pharmacy.
David M. Lee, M.D., Ph.D., is the global head of Autoimmunity, Dermatology and Transplantation Translational Medicine, a group within Novartis Institutes for Biomedical Research at Novartis Pharmaceuticals in Basel, Switzerland. Dr. Lee generates and implements Novartis' global disease translational medicine strategy to develop research discoveries into treatments. Previously, Lee was an associate professor at Harvard Medical School and associate physician at Brigham & Women's Hospital in Boston, focusing on translational studies of autoimmune and inflammatory mechanisms in arthritis. He earned his medical and graduate degrees from Duke University School of Medicine.
Lotus Mallbris, M.D., Ph.D., is the global medical lead across the tofacitinib investigational dermatology programs and senior medical director at Pfizer, Inc., and is based in Collegeville, Pa., outside Philadelphia. Dr. Mallbris brings more than a decade of experience in dermatology, clinical research, psoriasis and genetics. Dr. Mallbris earned her medical degree from Karolinska Institute in Stockholm and her doctorate in philosophy from the Institute's department of medicine, unit of dermatology.
Chris Russell, Ph.D., is a director in the molecular sciences department at Amgen, Inc., in Seattle. In his 12-year career at Amgen, Russell has supported their dermatology and rheumatology basic research programs, led biomarker discovery research across five different inflammation indications, and led biomarker programs for four molecules in phase I through phase III clinical trials. Russell brings expertise in inflammation, genomics, molecular biology and technology. Prior to Amgen, he was in the molecular technology department at Immunex, and at the Fred Hutchinson Cancer Research Center. He earned his doctorate of philosophy from the University of Oregon's Institute of Molecular Biology.
About the National Psoriasis Foundation
National Psoriasis Foundation (NPF) is the world's largest nonprofit serving those with psoriasis and psoriatic arthritis. Our priority is to provide the information and services people need to take control of their condition, while increasing research to find a cure. In addition to serving more than 2.1 million people annually through our health education and advocacy initiatives, NPF has funded more than $13 million in psoriatic disease research grants and fellowships. Learn more about the Psoriasis Foundation at www.psoriasis.org or call 800-723-9166. Follow us on Facebook and Twitter.